Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells [PDF]
Frontiers in Immunology, 2020 The cyclic VHCDR3-derived peptide (Rb9) from RebMab200 antibody, directed to a NaPi2B phosphate-transport protein, displayed anti-metastatic melanoma activity at 50–300 μg intraperitoneally injected in syngeneic mice.
Fabrício C. Machado +15 more
doaj +3 more sources
184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer [PDF]
, 2021 n/
Nicole Concin +19 more
openalex +4 more sources
PLoS ONE, 2013 NaPi2b, a sodium-dependent phosphate transporter, is highly expressed in ovarian carcinomas and is recognized by the murine monoclonal antibody MX35. The antibody had shown excellent targeting to ovarian cancer in several early phase clinical trials but ...
Mariana Lopes dos Santos +12 more
doaj +3 more sources
SLC34A2 Targets in Calcium/Phosphorus Homeostasis of Mammary Gland and Involvement in Development of Clinical Mastitis in Dairy Cows [PDF]
AnimalsThe type II Na/Pi co-transporter (NaPi2b), encoded by the solute carrier (SLC) transporter 34A2 (SLC34A2), is responsible for calcium (Ca) and phosphorus (P) homeostasis. Unbalanced Ca/P metabolism induces mastitis in dairy cows.
Xueying Wang +6 more
doaj +2 more sources
Journal of Clinical Oncology, 2022 3010 Background: XMT-1536 is a Dolaflexin ADC targeting the sodium-phosphate cotransporter NaPi2b, expressed in ovarian, non-squamous lung, papillary thyroid, endometrial, papillary renal and salivary duct cancers. Methods: In this ongoing Phase 1 study, pts with solid tumors likely to express NaPi2b, who progressed on standard therapy, are treated ...
Debra J. Richardson +14 more
+6 more sources
53P Expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy [PDF]
Annals of Oncology, 2021 A.K. Nurgalieva +8 more
openalex +3 more sources
Translational Pkpd of Dnib0600A, an Anti-Napi2B-Vc-Mmae Adc in Ovarian and Nsclc Cancers
Annals of Oncology, 2014 ABSTRACT Aim: Antibody-drug conjugates (ADCs) represent an expanding class of therapeutic molecules in preclinical and clinical development for oncologic indications. Understanding the relationship between pre-clinical to clinical studies with strategic application of pharmacokinetic/pharmacodynamics modeling may allow for optimized dosing strategies
KK Lin +7 more
openalex +3 more sources
Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells Include Increased TROP2 and Galectin-3 Levels. [PDF]
Cancer MedABSTRACT Background Endometrial cancer (EC) is the fourth most commonly diagnosed cancer among women in the US and the fifth leading cause of cancer death in this population. The FBXW7 tumor suppressor gene is frequently mutated in all molecular subtypes of EC.
Urick ME +3 more
europepmc +2 more sources
The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b [PDF]
Molecular Cancer Therapeutics, 2021 Abstract Target selection for antibody–drug conjugates (ADC) frequently focuses on identifying antigens with differential expression in tumor and normal tissue, to mitigate the risk of on-target toxicity. However, this strategy restricts the possible target space. SLC34A2/NaPi2b is a sodium phosphate transporter expressed in a variety of
Natalya D. Bodyak +23 more
openalex +5 more sources